Human adenoviral (HAdV) infections are usually mild and self-limited, however, some infections from species A, B, C, D and E, can cause severe illnesses, which have raised public health concerns over the past few years. Current available antiviral therapies have limited efficacy and severe toxicity; therefore, finding new targets for specific anti-adenoviral drug design is urgently needed. Our previous work showed that the small molecule compound, HBX, inhibits HAdV type 5 (species C, HAdV-C5) replication and oncogenic transformation through inhibition of the cellular pro-viral factor ubiquitin-specific protease 7 (USP7). Here, we have tested the ability of HBX to inhibit other HAdV species, as well as different clinical isolates that are the cause of severe infections.

中文翻译：

---

泛素化酶抑制剂HBX对人腺病毒的广谱抗病毒活性

人腺病毒（HAdV）感染通常是轻度且自限的，但是，一些来自A，B，C，D和E物种的感染会导致严重疾病，这在过去几年中引起了公众健康的关注。当前可用的抗病毒疗法具有有限的疗效和严重的毒性。因此，迫切需要找到针对特定抗腺病毒药物设计的新靶标。我们以前的工作表明，小分子化合物HBX通过抑制细胞前病毒因子泛素特异性蛋白酶7（USP7）抑制HAdV 5型（物种C，HAdV-C5）的复制和致癌性转化。在这里，我们测试了HBX抑制其他HAdV物种以及导致严重感染的不同临床分离株的能力。